Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.44 and traded as high as $2.53. Microbot Medical shares last traded at $2.23, with a volume of 2,045,535 shares.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a "buy" rating and set a $9.00 target price on shares of Microbot Medical in a research report on Thursday, April 10th.
View Our Latest Report on Microbot Medical
Microbot Medical Price Performance
The firm has a market cap of $90.68 million, a P/E ratio of -3.26 and a beta of 1.40. The company's 50-day moving average is $1.72 and its two-hundred day moving average is $1.48.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last issued its quarterly earnings results on Wednesday, March 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). On average, analysts expect that Microbot Medical Inc. will post -0.71 EPS for the current fiscal year.
Hedge Funds Weigh In On Microbot Medical
A hedge fund recently bought a new stake in Microbot Medical stock. Renaissance Technologies LLC bought a new stake in Microbot Medical Inc. (NASDAQ:MBOT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 105,658 shares of the biotechnology company's stock, valued at approximately $118,000. Renaissance Technologies LLC owned about 0.52% of Microbot Medical as of its most recent SEC filing. 16.30% of the stock is currently owned by institutional investors and hedge funds.
About Microbot Medical
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
See Also
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
